It suggests that an aCD20-based regimen produces clinical outcomes comparable to those of an aCD154-based regimen in wild-type pig-to-rhesus corneal xenotransplantation, whereas an aCD40-based regimen does not.
Lee et al. (Fri,) studied this question.